Excellent once-daily oral ABX464 efficacy and safety data in the phase 2b clinical trial in ulcerative colitis (UC) patients, previously reported at 8-weeks, are further improved at 16-weeks

Additional analyses (incl. miR-124 levels, histopathology, quality of life, etc.) underpin the potential of ABX464 to become a safe short- and long-term efficient treatment option in UC

Novel and highly differentiated mechanism of action of ABX464 confirmed, showing specific upregulation of a single microRNA, miR-124

Additional long-term data of the ABX464 phase 2a open-label maintenance study in UC confirm the good safety and potent efficacy of ABX464 after 3 years of continuous chronic treatment

For the launch of its phase 3 program in UC, Abivax is getting ready for the mandatory consultations with the regulatory authorities, starting with feedback from the US regulatory agency (FDA) expected by year end

Abivax’ late breaking abstract on the phase 2b data in UC was selected for oral presenta-tion during UEG Week Virtual 2021 (Monday, October 4). The data will be presented by the study’s principal investigator, Prof. Séverine Vermeire, M.D., Ph.D.

Also, on the same day at UEG Week Virtual 2021, Abivax will host a Live Industry Symposium with presentations by key opinion leaders Prof. Bruce Sands, M.D., M.S. and Prof. William Sandborn, M.D.